TICKERNERD
Menu
LRMRLRMRHealthcare · Biotechnology

LRMR Stock Forecast: Larimar Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$4.36
+2.11% on the day

The 11 Wall Street analysts covering Larimar Therapeutics, Inc. hold a median 12-month price target of $13 — +186.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$452.9M
Ticker Nerd rank
35 / 100
Median analyst target
$13
Analysts covering
11
Total return, dividends reinvested
1W
+4.8%
1M
+17.2%
YTD
+14.4%
1Y
+2.3%
From 52W high
−26.7%
From 52W low
+55.2%
$2.81
$5.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LRMR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Larimar Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
73
Accruals
68
Momentum
66
Size
55
Volatility
44
Value
31
Issuance
23
Growth
22
Quality
17

Revisions (73): Analysts have, on balance, been raising their forecasts.

Quality (17): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LRMR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LRMR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26LRMRHigh $26Median $13Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $5Median $13High $26

The green dot is the last close — the median target sits +186.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026WedbushMaintainsOutperform$12 → $11
2 July 2026HC Wainwright & Co.AssumesBuy$10
30 June 2026BairdMaintainsOutperform$7.00 → $5.00
30 June 2026BairdMaintainsOutperform—
27 May 2026JP MorganInitiatesOverweight—
18 May 2026WedbushMaintainsOutperform—
20 Mar 2026WedbushMaintainsOutperform—
3 Mar 2026WedbushMaintainsOutperform—
25 Feb 2026CitigroupMaintainsBuy—
25 Feb 2026WedbushReiteratesOutperform—
2 Oct 2025OppenheimerMaintainsOutperform—
30 Sept 2025BairdMaintainsOutperform—
30 Sept 2025WedbushMaintainsOutperform—
19 Aug 2025JMP SecuritiesReiteratesMarket Outperform—
15 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
25 June 2025GuggenheimReiteratesBuy—
24 June 2025GuggenheimReiteratesBuy—
24 June 2025WedbushMaintainsOutperform—
25 Mar 2025BairdMaintainsOutperform—
25 Mar 2025GuggenheimReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LRMR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LRMR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Larimar Therapeutics, Inc. (LRMR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.9×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
3.6×

Cheaper than 30% of US stocks

EV / EBITDA
−1.7×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−139.6%

Higher than 10% of US stocks

Return on assets
−71.0%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LRMR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LRMRLarimar Therapeutics, Inc.$452.9M
35
OCGNOcugen, Inc.$457.0M
24
QTTBQ32 Bio, Inc.$450.9M
86
PBYIPuma Biotechnology, Inc.$449.4M
99
CABACabaletta Bio, Inc.$448.4M
28
PRTAProthena Corp. Plc$476.9M
98
RZLTRezolute, Inc.$440.2M
34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Larimar Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LRMR news & analysis

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

GlobeNewsWire · 4 Aug 2026neutral

Larimar Therapeutics reported its second quarter 2026 operating and financial results in a business update on August 4, 2026. The clinical-stage biotechnology company, which focuses on treatments for rare diseases, disclosed its quarterly financial and operational progress.

Why it matters — LRMR watchers would care because the quarterly update provides insight into the company's financial health and operational status, including its progress in developing treatments for complex rare diseases.

FAQ

Frequently asked questions about LRMR stock

What is the LRMR stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Larimar Therapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $5 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LRMR stock a buy right now?

Of the 11 analysts covering Larimar Therapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Larimar Therapeutics, Inc. 35 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LRMR?

As at 15 Aug 2026, Larimar Therapeutics, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (73 of 100).

Will LRMR stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +186.7% from the last close, and Ticker Nerd's factor model ranks Larimar Therapeutics, Inc. 35 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LRMR stock forecast for 2030?

No analyst covering Larimar Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LRMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $26 over the next 12 months.

How has LRMR stock performed over the past year?

Larimar Therapeutics, Inc. returned +2.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Larimar Therapeutics, Inc. do?

Larimar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its proprietary cell-penetrating peptide technology platform.

What is the latest news on LRMR?

The most recent item we track (GlobeNewsWire, 4 Aug 2026): "Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update". Larimar Therapeutics reported its second quarter 2026 operating and financial results in a business update on August 4, 2026. The clinical-stage biotechnology company, which focuses on treatments for rare diseases, disclosed its quarterly financial and operational progress.

Company

About Larimar Therapeutics, Inc.

Larimar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its proprietary cell-penetrating peptide technology platform. This platform enables intracellular delivery of missing proteins to address devastating conditions with limited or no available therapies. The company's lead product candidate, nomlabofusp, is in Phase 2 clinical trials, including ongoing long-term open-label and open-label extension studies, for Friedreich’s ataxia, a rare, progressive genetic disease caused by frataxin deficiency. Nomlabofusp aims to restore frataxin protein levels, with data showing increases in skin frataxin concentrations and directional improvements in clinical measures. Larimar Therapeutics Inc. is advancing nomlabofusp toward potential regulatory submissions and also plans to apply its platform to other rare diseases involving intracellular protein deficiencies. Headquartered in Bala Cynwyd, Pennsylvania, the company plays a key role in the rare disease biotechnology sector by targeting unmet needs in mitochondrial and genetic disorders.

CEO Dr. Carole S. Ben-Maimon M.D. · 71 employees · United States · https://www.larimartx.com